Essayer OR - Gratuit
Leprosy Isn't Over: South-East Asia's Unfinished Fight
BioSpectrum Asia
|BioSpectrum Asia Feb 2026
As we commemorate World Leprosy Day on January 25, the global community is oldest diseases-has not yet been consigned to history.
Nowhere is this more evident than in the South-East Asia Region, which continues to shoulder the largest share of the global leprosy burden. While remarkable progress has been made, the persistence of new cases underscores an urgent truth: leprosy is curable, but elimination demands far more than medicine alone.
South-East Asia accounts for the majority of newly detected leprosy cases worldwide. According to a WHO report released on January 23, 2026, India and Indonesia continue to report more than 10,000 new cases annually, while countries such as Bangladesh, Myanmar, Nepal and Sri Lanka report thousands more. This mirrors global trends from 2024, when Brazil, India and Indonesia together accounted for the highest number of cases, even as 55 countries reported zero cases. Poverty, overcrowded living conditions, limited access to health services and social marginalisation continue to create fertile ground for transmission.
Cette histoire est tirée de l'édition BioSpectrum Asia Feb 2026 de BioSpectrum Asia.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE BioSpectrum Asia
BioSpectrum Asia
The Race to Build Singapore's Biotech Unicorns
MIRXES, known for its work in early cancer detection and backed by A*STAR and the National University of Singapore, became Southeast Asia's first biotech unicorn when it listed on the Hong Kong Exchange in 2025.
5 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
BIRAC inks Letter of Intent with Global Antibiotic Research & Development Partnership
Biotechnology Industry Research Assistance Council (BIRAC), under the Department of Biotechnology (DBT), Government of India, has announced a Letter of Intent (LOI) with the Global Antibiotic Research & Development Partnership (GARDP), a Swiss not-forprofit organisation that develops new antibiotic treatments for drug-resistant bacterial infections that pose the greatest threat to human health.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
"Neuroinflammation is not only a hallmark of Alzheimer's disease but a key pathological feature in other neurodegenerative disorders"
As dementia becomes the leading cause of death in Australia and Alzheimer’s disease continues to affect millions worldwide, the urgency for fundamentally new treatment strategies has never been clearer.
4 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Leprosy Isn't Over: South-East Asia's Unfinished Fight
As we commemorate World Leprosy Day on January 25, the global community is oldest diseases-has not yet been consigned to history.
2 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
"Absence of a widespread infectious disease emergency in 2025 has hindered progress in combating AMR"
After decades of incremental antibiotic innovation, antimicrobial resistance (AMR) is outpacing our ability to respond, and 2026 may mark a breaking point.
5 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
The Strategic Rise of India's Deep-Science Economy
India is emerging as a powerful hub for deep science and biotechnology, driven by favourable geopolitics, a large domestic market, strong pharmaceutical and chemicals infrastructure, and supportive government policies.
4 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Japan strengthening biopharma capabilities
Asia's biopharma landscape is shifting rapidly toward innovation, with countries such as South Korea, Singapore, India, and Taiwan advancing R&D capabilities.
7 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Cancer Diagnosis, Accelerated by AI
Cancer remains a leading cause of death worldwide, with Asia bearing a disproportionate burden.
13 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Beyond Companion Diagnostics: How Biomarkers and Digital Technologies Will Reshape Oncology Care in Asia by 2026
The oncology landscape in Asia stands at a critical juncture.
5 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Pharma M&A set to boom in 2026
After years of unspectacular Mergers and Acquisitions (M&A) activity, 2025 recorded some of the largest pharma deals.
3 mins
BioSpectrum Asia Feb 2026
Listen
Translate
Change font size
